Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 232 publications
Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.
Journal: Obesity pillars
Published: July 28, 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity.
Journal: The New England journal of medicine
Published: June 08, 2026
Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.
Journal: Obesity pillars
Published: May 06, 2026
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal: Journal of medical economics
Published: April 21, 2026
Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.
Journal: Obesity (Silver Spring, Md.)
Published: April 13, 2026
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
Journal: The lancet. Diabetes & endocrinology
Published: April 02, 2026
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 12, 2026
New era in obesity medication access: A commentary.
Journal: Obesity pillars
Published: December 20, 2025
Correction: Quality of life improvements associated with weight loss using a novel shape-shifting hydrogel capsule: RESET study results.
Journal: International journal of obesity (2005)
Published: November 13, 2025
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: September 29, 2025
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
Journal: Obesity (Silver Spring, Md.)
Published: July 25, 2025
Last Updated: 09/26/2026